Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells $46,822.02 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman sold 1,702 shares of the firm’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $27.51, for a total value of $46,822.02. Following the transaction, the director now directly owns 131,643 shares of the company’s stock, valued at approximately $3,621,498.93. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Enliven Therapeutics Stock Performance

Enliven Therapeutics stock traded down $1.48 during midday trading on Friday, reaching $23.22. The stock had a trading volume of 261,164 shares, compared to its average volume of 273,318. Enliven Therapeutics, Inc. has a twelve month low of $9.80 and a twelve month high of $27.67. The stock has a market capitalization of $1.09 billion, a PE ratio of -11.66 and a beta of 1.10. The stock’s 50-day simple moving average is $22.84 and its 200 day simple moving average is $19.49.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Tuesday, May 14th. The company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.04. Equities analysts predict that Enliven Therapeutics, Inc. will post -2.26 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ELVN. Janus Henderson Group PLC lifted its stake in shares of Enliven Therapeutics by 74.8% during the first quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock worth $12,604,000 after purchasing an additional 305,397 shares in the last quarter. Baker BROS. Advisors LP acquired a new position in shares of Enliven Therapeutics during the first quarter worth about $2,020,000. Bank of New York Mellon Corp increased its position in shares of Enliven Therapeutics by 49.2% during the second quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company’s stock worth $2,667,000 after acquiring an additional 37,632 shares during the last quarter. Rhumbline Advisers increased its position in shares of Enliven Therapeutics by 29.9% during the second quarter. Rhumbline Advisers now owns 49,627 shares of the company’s stock worth $1,160,000 after acquiring an additional 11,420 shares during the last quarter. Finally, Blackstone Inc. purchased a new stake in shares of Enliven Therapeutics during the first quarter worth about $443,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Baird R W raised Enliven Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th. Robert W. Baird assumed coverage on Enliven Therapeutics in a research report on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 price objective for the company. Finally, Mizuho assumed coverage on Enliven Therapeutics in a research report on Tuesday, April 9th. They issued a “buy” rating and a $34.00 price objective for the company.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.